Volpara share price charges higher after completing MRS Systems acquisition

The Volpara Health Technologies Ltd (ASX:VHT) share price is raced higher again on Friday. Here’s why…

| More on:
Healthcare technology shares

The Volpara Health Technologies Ltd (ASX: VHT) share price is on course to finish the week with a strong gain.

On Friday afternoon the medical technology company’s shares are up almost 5.5% to $1.69.

Why is the Volpara share price charging higher?

Investors appear to have been scrambling to pick up the company’s shares today after it announced the completion of its US$14.59 million (~A$21.15 million) acquisition of MRS Systems.

MRS Systems is a medical software company that provides comprehensive patient tracking and communication, and a radiology reporting platform for sub-specialty radiology applications including breast and lung imaging.

It is a leading provider of breast clinic management software, with an estimated ~20% market share of breast clinics in the United States.

In the 2019 calendar year the company has forecast annual recurring revenue (ARR) of ~US$4.5 million. Including capital sales, MRS Systems expects ~US$7.5 million of total revenue over the 12 months.

Volpara made the acquisition as it provides it with an expanded and mature presence in the United States, an enlarged sales footprint and technical support, and product suites that are highly complementary. The latter is expected to provide both businesses with cross-selling opportunities.

In addition to this, management believes the combination of MRS clinical data and Volpara images will enrich Volpara’s AI capability.

Volpara’s CEO, Dr Ralph Highnam, said: “We are delighted to welcome MRS Systems and its people into the Volpara group. And we are excited about the opportunity to work alongside MRS Systems in the United States and to grow Volpara’s service offering in the increased number of US breast clinics to which Volpara now has immediate access. The acquisition has involved a tremendous effort from people in both organisations, and I would like to express my thanks to everyone as we look forward to the future with a stronger US base and an extended range of integrated products which will help detect breast cancer earlier.”

Volpara isn’t the only medical technology company on the rise today. The shares of both Nanosonics Ltd (ASX: NAN) and Pro Medicus Limited (ASX: PME) are outperforming the market by some distance on Friday.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of VOLPARA FPO NZ. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited and Pro Medicus Ltd. The Motley Fool Australia has recommended VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers